The global critical care antiarrhythmic drugs market size is projected to reach USD 1,319.7 million by 2027, exhibiting a CAGR of 5.6% during the forecast period. Increasing prevalence of cardiovascular diseases (CVDs) around the world will be a major growth determinant for this market, highlights Fortune Business Insights™ in its report, titled “Critical Care Antiarrhythmic Drugs Market Size, Share & COVID-19 Impact Analysis, By Drug Class (Beta Blockers, Calcium Channel Blockers, Sodium Channel Blockers, Potassium Channel Blockers, and Others), By Disease Type (Supraventricular Arrhythmias, Ventricular Arrhythmias, and Others), and Regional Forecast, 2020-2027”.
According to the World Health Organization (WHO), CVDs are the premier cause of global deaths, killing nearly 17.9 million people worldwide in 2016. Atrial fibrillation (AF) is the most frequent and the most commonly observed CVD. For example, the American Heart Association estimates that AF affects around 2.2 million people in the United States. More importantly, the incidence of AF is steadily rising. A study conducted by the Erasmus Medical Center in the Netherlands found that approximately 17.9 million people across Europe will be afflicted by AF in 2060. A similar epidemiological study conducted by researchers at the University of Arkansas revealed that in the US, between 6 million and 12 million people will suffer from AF by 2050. These projections indicate a steady rise in the demand for critical care antiarrhythmic drugs in the forthcoming decades as cardiac arrhythmia can turn fatal if not treated with effective medication in time.
Request a Sample Copy of the Research Report:
As per the report findings, the global market value stood at USD 796.8 million in 2019. The report also shares market information in the following manner:
- Careful projections about the upcoming trends and prospects in the market;
- Unmatched research into the regional dynamics of the market;
- Granular analysis of the factors driving and restraining the market; and
- Exhaustive profiling and examination of the key market players and their dominant strategies.
Growing Importance of Heart Health amid COVID-19 to Boost the Market
The COVID-19 pandemic has reiterated the importance of maintaining heart health as patients suffering from heart-related comorbidities have been found to be at high risk of contracting the coronavirus. Early evidence from China’s Hubei and Wuhan provinces shows that 16.7% of the hospitalized patients and 44.4% of patients in intensive care units (ICUs) had cardiac arrhythmia. Another study conducted by researchers from the Perelman School of Medicine at the University of Pennsylvania in July 2020 revealed that the onset of the COVID-19 infection was associated with a high incidence of cardiac arrhythmias in patients.
While the coronavirus is not solely responsible for the occurrence of cardiac abnormalities, the infection, in many cases, has worsened the preexisting conditions, leading to higher mortality rates among patients with chronic heart diseases. The coronavirus has, thus, heightened the adoption of critical care anti-arrhythmogenic drugs worldwide. The global market has, as a result, registered a CAGR of 12.9% in 2020.
Click here to get the short-term and long-term impact of COVID-19 on this market.
Please visit: https://www.fortunebusinessinsights.com/critical-care-antiarrhythmic-drugs-market-104703
About Us:
Fortune Business Insights™ delivers accurate data and innovative corporate analysis, helping organizations of all sizes make appropriate decisions. We tailor novel solutions for our clients, assisting them to address various challenges distinct to their businesses. Our aim is to empower them with holistic market intelligence, providing a granular overview of the market they are operating in.
Contact Us:
Fortune Business Insights™ Pvt. Ltd
U.S.: +1 424 253 0390
U.K.: +44 2071 939123
APAC: +91 744 740 1245
Email: [email protected]
Arabic
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Greek